15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Heron Therapeuti, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $2.00 to $3.00, a moderate spread. The average target of $2.50 sits 415% above the current $0.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.02 next quarter toward $0.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Heron Therapeuti.
As of Jul, 1 of 2 firms rate HRTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HRTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -45% YoY
Next period, 1 analysts expect Heron Therapeuti to earn $-0.02 a share (range $-0.02 – $-0.02), versus $-0.04 a year earlier. Full-year consensus is $-0.09, growing to $0.00 the year after.
REVENUE · NEXT QUARTER
$42.0M
Range $40.6M – $43.3M · 1 analysts · +10% YoY
Revenue is expected to reach $42.0M (range $40.6M – $43.3M), +9.8% year-over-year. Full-year consensus is $165.7M, rising to $175.9M next year.
Top analysts covering Heron Therapeuti
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HRTX.
#1
Serge Belanger
Needham · Rank #83
Hold
No targeton HRTX
Overall win rate
48%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$2.00+311.8% to target
Coverage
—
+ Follow
#3
Carl Byrnes
Northland Capital Markets
Buy
$4.00+723.6% to target
Coverage
—
+ Follow
#4
CD
Clara Dong
Jefferies
Buy
$5.00+929.4% to target
Coverage
—
+ Follow
HRTX stock forecast FAQ
What is HRTX's average 12-month price target?+
The 1 analysts with a live target average $2.50 for Heron Therapeuti over the next 12 months, ranging from a $3.00 high to a $2.00 low.
Is HRTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HRTX?+
The Street-high target is $3.00, and the Street-low is $2.00 (HC Wainwright & Co.). The average of all 1 active targets is $2.50.
How many Wall Street analysts cover HRTX?+
2 analysts have an active rating on Heron Therapeuti, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering HRTX?+
Among analysts who currently cover HRTX, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #83). Their current call is Hold.
What is Heron Therapeuti's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $-0.09, rising to $0.00 the following year.
How much revenue is Heron Therapeuti expected to report next quarter?+
Consensus revenue is $42.0M (range $40.6M – $43.3M). Full-year revenue is projected at $165.7M, growing to $175.9M next year.
Have analysts been upgrading or downgrading HRTX lately?+
As of Jul, 1 of 2 firms rate HRTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
